Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
49
LXEO Quote, Financials, Valuation and Earnings
Last price:
$9.49
Seasonality move
:
-53.42%
Day range:
$9.11 - $9.45
52-week range:
$1.45 - $10.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.57x
Volume:
920.7K
Avg. volume:
1.3M
1-year change:
32.06%
Market cap:
$310.3M
Revenue:
--
EPS (TTM):
-$2.70
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LXEO
Lexeo Therapeutics, Inc.
|
-- | -$0.46 | -- | -60.81% | $19.40 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$277.2M | $0.15 | 12.73% | -82.4% | $29.05 |
|
ANIX
Anixa Biosciences, Inc.
|
-- | -$0.09 | -100% | -0.45% | $9.00 |
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
MBRX
Moleculin Biotech, Inc.
|
-- | -- | -- | -- | $6.67 |
|
SPRB
Spruce Biosciences
|
-- | -$20.25 | -100% | -98.48% | $1.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LXEO
Lexeo Therapeutics, Inc.
|
$9.35 | $19.40 | $310.3M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$27.44 | $29.05 | $4.6B | 17.66x | $0.00 | 0% | 4.41x |
|
ANIX
Anixa Biosciences, Inc.
|
$4.79 | $9.00 | $157.7M | -- | $0.00 | 0% | -- |
|
GTBP
GT Biopharma, Inc.
|
$0.61 | $8.00 | $6.5M | -- | $0.00 | 0% | 59.35x |
|
MBRX
Moleculin Biotech, Inc.
|
$7.24 | $6.67 | $15M | -- | $0.00 | 0% | -- |
|
SPRB
Spruce Biosciences
|
$0.14 | $1.00 | $76K | -- | $0.00 | 0% | 0.02x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LXEO
Lexeo Therapeutics, Inc.
|
6.54% | 1.568 | 3.84% | 7.11x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.330 | 1.52% | 2.70x |
|
ANIX
Anixa Biosciences, Inc.
|
1.27% | 2.400 | 0.21% | 7.76x |
|
GTBP
GT Biopharma, Inc.
|
-- | -0.510 | 4.06% | 1.98x |
|
MBRX
Moleculin Biotech, Inc.
|
-1.47% | 1.294 | 1.49% | 1.18x |
|
SPRB
Spruce Biosciences
|
3.99% | 2.548 | 10.94% | 5.06x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LXEO
Lexeo Therapeutics, Inc.
|
-$530K | -$21.6M | -80.69% | -86.99% | -- | -$29.8M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ANIX
Anixa Biosciences, Inc.
|
-$9K | -$2.4M | -63.93% | -64.77% | -- | -$1.5M |
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
MBRX
Moleculin Biotech, Inc.
|
-$21K | -$5.9M | -502.35% | -552.21% | -- | -$7.2M |
|
SPRB
Spruce Biosciences
|
-- | -$14.5M | -55.68% | -58.1% | -1428.57% | -$12.7M |
Lexeo Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns LXEO or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Lexeo Therapeutics, Inc.'s net margin of 25.76%. Lexeo Therapeutics, Inc.'s return on equity of -86.99% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital LXEOLexeo Therapeutics, Inc.-- -$0.33 $129.3M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About LXEO or ACAD?
Lexeo Therapeutics, Inc. has a consensus price target of $19.40, signalling upside risk potential of 107.49%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $29.05 which suggests that it could grow by 5.88%. Given that Lexeo Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Lexeo Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LXEOLexeo Therapeutics, Inc.8 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is LXEO or ACAD More Risky?
Lexeo Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.982%.
-
Which is a Better Dividend Stock LXEO or ACAD?
Lexeo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexeo Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LXEO or ACAD?
Lexeo Therapeutics, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Lexeo Therapeutics, Inc.'s net income of -$20.3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Lexeo Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 17.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexeo Therapeutics, Inc. is -- versus 4.41x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LXEOLexeo Therapeutics, Inc.-- -- -- -$20.3M ACADACADIA Pharmaceuticals, Inc.4.41x 17.66x $278.6M $71.8M
-
Which has Higher Returns LXEO or ANIX?
Anixa Biosciences, Inc. has a net margin of -- compared to Lexeo Therapeutics, Inc.'s net margin of --. Lexeo Therapeutics, Inc.'s return on equity of -86.99% beat Anixa Biosciences, Inc.'s return on equity of -64.77%.
Company Gross Margin Earnings Per Share Invested Capital LXEOLexeo Therapeutics, Inc.-- -$0.33 $129.3M ANIXAnixa Biosciences, Inc.-- -$0.07 $15.6M -
What do Analysts Say About LXEO or ANIX?
Lexeo Therapeutics, Inc. has a consensus price target of $19.40, signalling upside risk potential of 107.49%. On the other hand Anixa Biosciences, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 108.77%. Given that Anixa Biosciences, Inc. has higher upside potential than Lexeo Therapeutics, Inc., analysts believe Anixa Biosciences, Inc. is more attractive than Lexeo Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LXEOLexeo Therapeutics, Inc.8 0 0 ANIXAnixa Biosciences, Inc.2 0 0 -
Is LXEO or ANIX More Risky?
Lexeo Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Anixa Biosciences, Inc. has a beta of 0.488, suggesting its less volatile than the S&P 500 by 51.221%.
-
Which is a Better Dividend Stock LXEO or ANIX?
Lexeo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anixa Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexeo Therapeutics, Inc. pays -- of its earnings as a dividend. Anixa Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LXEO or ANIX?
Lexeo Therapeutics, Inc. quarterly revenues are --, which are smaller than Anixa Biosciences, Inc. quarterly revenues of --. Lexeo Therapeutics, Inc.'s net income of -$20.3M is lower than Anixa Biosciences, Inc.'s net income of -$2.3M. Notably, Lexeo Therapeutics, Inc.'s price-to-earnings ratio is -- while Anixa Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexeo Therapeutics, Inc. is -- versus -- for Anixa Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LXEOLexeo Therapeutics, Inc.-- -- -- -$20.3M ANIXAnixa Biosciences, Inc.-- -- -- -$2.3M
-
Which has Higher Returns LXEO or GTBP?
GT Biopharma, Inc. has a net margin of -- compared to Lexeo Therapeutics, Inc.'s net margin of --. Lexeo Therapeutics, Inc.'s return on equity of -86.99% beat GT Biopharma, Inc.'s return on equity of -626.24%.
Company Gross Margin Earnings Per Share Invested Capital LXEOLexeo Therapeutics, Inc.-- -$0.33 $129.3M GTBPGT Biopharma, Inc.-- -$0.83 $3M -
What do Analysts Say About LXEO or GTBP?
Lexeo Therapeutics, Inc. has a consensus price target of $19.40, signalling upside risk potential of 107.49%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 1212.77%. Given that GT Biopharma, Inc. has higher upside potential than Lexeo Therapeutics, Inc., analysts believe GT Biopharma, Inc. is more attractive than Lexeo Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LXEOLexeo Therapeutics, Inc.8 0 0 GTBPGT Biopharma, Inc.1 0 0 -
Is LXEO or GTBP More Risky?
Lexeo Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.
-
Which is a Better Dividend Stock LXEO or GTBP?
Lexeo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexeo Therapeutics, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LXEO or GTBP?
Lexeo Therapeutics, Inc. quarterly revenues are --, which are smaller than GT Biopharma, Inc. quarterly revenues of --. Lexeo Therapeutics, Inc.'s net income of -$20.3M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Lexeo Therapeutics, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexeo Therapeutics, Inc. is -- versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LXEOLexeo Therapeutics, Inc.-- -- -- -$20.3M GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M
-
Which has Higher Returns LXEO or MBRX?
Moleculin Biotech, Inc. has a net margin of -- compared to Lexeo Therapeutics, Inc.'s net margin of --. Lexeo Therapeutics, Inc.'s return on equity of -86.99% beat Moleculin Biotech, Inc.'s return on equity of -552.21%.
Company Gross Margin Earnings Per Share Invested Capital LXEOLexeo Therapeutics, Inc.-- -$0.33 $129.3M MBRXMoleculin Biotech, Inc.-- -$17.02 -$26.5M -
What do Analysts Say About LXEO or MBRX?
Lexeo Therapeutics, Inc. has a consensus price target of $19.40, signalling upside risk potential of 107.49%. On the other hand Moleculin Biotech, Inc. has an analysts' consensus of $6.67 which suggests that it could grow by 2202.03%. Given that Moleculin Biotech, Inc. has higher upside potential than Lexeo Therapeutics, Inc., analysts believe Moleculin Biotech, Inc. is more attractive than Lexeo Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LXEOLexeo Therapeutics, Inc.8 0 0 MBRXMoleculin Biotech, Inc.2 0 0 -
Is LXEO or MBRX More Risky?
Lexeo Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moleculin Biotech, Inc. has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.192%.
-
Which is a Better Dividend Stock LXEO or MBRX?
Lexeo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moleculin Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexeo Therapeutics, Inc. pays -- of its earnings as a dividend. Moleculin Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LXEO or MBRX?
Lexeo Therapeutics, Inc. quarterly revenues are --, which are smaller than Moleculin Biotech, Inc. quarterly revenues of --. Lexeo Therapeutics, Inc.'s net income of -$20.3M is higher than Moleculin Biotech, Inc.'s net income of -$25.4M. Notably, Lexeo Therapeutics, Inc.'s price-to-earnings ratio is -- while Moleculin Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexeo Therapeutics, Inc. is -- versus -- for Moleculin Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LXEOLexeo Therapeutics, Inc.-- -- -- -$20.3M MBRXMoleculin Biotech, Inc.-- -- -- -$25.4M
-
Which has Higher Returns LXEO or SPRB?
Spruce Biosciences has a net margin of -- compared to Lexeo Therapeutics, Inc.'s net margin of -1440.37%. Lexeo Therapeutics, Inc.'s return on equity of -86.99% beat Spruce Biosciences's return on equity of -58.1%.
Company Gross Margin Earnings Per Share Invested Capital LXEOLexeo Therapeutics, Inc.-- -$0.33 $129.3M SPRBSpruce Biosciences-- -$0.32 $53.8M -
What do Analysts Say About LXEO or SPRB?
Lexeo Therapeutics, Inc. has a consensus price target of $19.40, signalling upside risk potential of 107.49%. On the other hand Spruce Biosciences has an analysts' consensus of $1.00 which suggests that it could grow by 640.74%. Given that Spruce Biosciences has higher upside potential than Lexeo Therapeutics, Inc., analysts believe Spruce Biosciences is more attractive than Lexeo Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LXEOLexeo Therapeutics, Inc.8 0 0 SPRBSpruce Biosciences0 2 0 -
Is LXEO or SPRB More Risky?
Lexeo Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spruce Biosciences has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LXEO or SPRB?
Lexeo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spruce Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexeo Therapeutics, Inc. pays -- of its earnings as a dividend. Spruce Biosciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LXEO or SPRB?
Lexeo Therapeutics, Inc. quarterly revenues are --, which are smaller than Spruce Biosciences quarterly revenues of $602K. Lexeo Therapeutics, Inc.'s net income of -$20.3M is lower than Spruce Biosciences's net income of -$14M. Notably, Lexeo Therapeutics, Inc.'s price-to-earnings ratio is -- while Spruce Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexeo Therapeutics, Inc. is -- versus 0.02x for Spruce Biosciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LXEOLexeo Therapeutics, Inc.-- -- -- -$20.3M SPRBSpruce Biosciences0.02x -- $602K -$14M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 65.44% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 8.33% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.85% over the past day.
